<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00021814</url>
  </required_header>
  <id_info>
    <org_study_id>MTOPS (completed)</org_study_id>
    <secondary_id>U01DK046472</secondary_id>
    <nct_id>NCT00021814</nct_id>
  </id_info>
  <brief_title>Medical Therapy of Prostatic Symptoms (MTOPS)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <brief_summary>
    <textblock>
      The Medical Therapy of Prostatic Symptoms (MTOPS) is a clinical research study sponsored by
      the National Institutes of Health (NIH). The study will test whether the oral drugs
      finasteride (Proscar) and doxazosin (Cardura), alone or together, can delay or prevent
      further worsening of symptoms in men with Benign Prostatic Hyperplasia (BPH).

      MTOPS is the largest and longest study to simultaneously test whether these drugs can delay
      or prevent the clinical progression (symptom worsening) of BPH. Seventeen U.S. medical
      centers recruited 2,931 men diagnosed with symptomatic BPH between December 1995 and March
      1998. Study doctors will continue to follow these men through November 2001 on a quarterly
      basis. In addition to the clinical progression of BPH, MTOPS will include evaluations of
      prostate volume by ultrasound, prostate biopsies among a subgroup of volunteers, and quality
      of life.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 1995</start_date>
  <completion_date>March 1998</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>2931</enrollment>
  <condition>Prostatic Hyperplasia</condition>
  <condition>Prostatic Hypertrophy, Benign</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxazosin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Finasteride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Peak urinary flow rate at least 4 ml/sec but not greater than 15 ml/sec; and voided
             volume is at least 125 ml.

          -  American Urological Association Symptom Score is greater than or equal to 8 and less
             than or equal to 30.

          -  Voluntarily signed the informed consent agreement prior to the performance of any
             study procedures.

        Exclusion Criteria:

          -  Serum prostate specific antigen level greater than 10 ng/ml.

          -  Supine blood pressure less than 90/70 mmHG. Orthostatic hypotension.

          -  Any prior medical or surgical intervention for BPH.

          -  Received any prior experimental intervention (either medical or surgical) for prostate
             disease or enrolled in any other study protocol.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E. David Crawford</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic 01 - Univ of Colorado Health Sciences Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven A. Kaplan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic 02 - New York Presbyterian Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Claus Roehrborn</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic 03 - UT Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Noah S. Schenkman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic 04 - Walter Reed Army Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Herbert Lepor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic 06 - New York University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin M. Slawin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic 07 - Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John P. Foley</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic 08 - Brooke Army Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joe W. Ramsdell</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic 09 - University of California San Diego</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mani Menon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic 10 - Henry Ford Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael M. Lieber</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic 11 - Mayo Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin T. McVary</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic 12 - Northwestern University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph A. Smith</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic 13 - Vanderbilt University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerald L. Andriole</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic 14 - Washington University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harris E. Foster</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic 15 - Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harry S. Clarke</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic 16 - Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karl J. Kreder</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic 17 - University of Iowa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen C. Jacobs</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic 18 - University of Maryland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gary J. Miller</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diagnostic Center - Univ of Colorado Health Sciences Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oliver M. Bautista</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biostatistical Coordinating Center - George Washington Univ.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0694</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Colorado Health Sciences Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80010-0510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter Reed Army Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health Systems</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Foundation</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Presbyterian Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-2765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>5235-9110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooke Army Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78234-6200</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bsc.gwu.edu/mtops/index.html</url>
    <description>MTOPS public access site. Userid and password not required.</description>
  </link>
  <reference>
    <citation>Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984 Sep;132(3):474-9.</citation>
    <PMID>6206240</PMID>
  </reference>
  <reference>
    <citation>Sidney S, Quesenberry CP Jr, Sadler MC, Guess HA, Lydick EG, Cattolica EV. Incidence of surgically treated benign prostatic hypertrophy and of prostate cancer among blacks and whites in a prepaid health care plan. Am J Epidemiol. 1991 Oct 15;134(8):825-9.</citation>
    <PMID>1719806</PMID>
  </reference>
  <reference>
    <citation>Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med. 1992 Oct 22;327(17):1185-91.</citation>
    <PMID>1383816</PMID>
  </reference>
  <reference>
    <citation>Lepor H, Gup DI, Baumann M, Shapiro E. Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia. Urology. 1988 Dec;32(6 Suppl):21-6.</citation>
    <PMID>2462301</PMID>
  </reference>
  <reference>
    <citation>Lepor H, Henry D, Laddu AR. The efficacy and safety of terazosin for the treatment of symptomatic BPH. Prostate. 1991;18(4):345-55. Review.</citation>
    <PMID>1711689</PMID>
  </reference>
  <reference>
    <citation>Guess HA. Benign prostatic hyperplasia: antecedents and natural history. Epidemiol Rev. 1992;14:131-53. Review.</citation>
    <PMID>1283852</PMID>
  </reference>
  <reference>
    <citation>McConnell JD. Androgen ablation and blockade in the treatment of benign prostatic hyperplasia. Urol Clin North Am. 1990 Aug;17(3):661-70. Review.</citation>
    <PMID>1695786</PMID>
  </reference>
  <reference>
    <citation>Barry MJ. Epidemiology and natural history of benign prostatic hyperplasia. Urol Clin North Am. 1990 Aug;17(3):495-507. Review.</citation>
    <PMID>1695778</PMID>
  </reference>
  <reference>
    <citation>Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol. 1989 Feb;141(2):243-7.</citation>
    <PMID>2643719</PMID>
  </reference>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2001</study_first_submitted>
  <study_first_submitted_qc>August 3, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2001</study_first_posted>
  <last_update_submitted>January 12, 2010</last_update_submitted>
  <last_update_submitted_qc>January 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2010</last_update_posted>
  <keyword>BPH progression</keyword>
  <keyword>Medical Therapy</keyword>
  <keyword>Finasteride</keyword>
  <keyword>Doxazosin</keyword>
  <keyword>Randomized</keyword>
  <keyword>Multi-center</keyword>
  <keyword>Clinical Trial</keyword>
  <keyword>Proscar</keyword>
  <keyword>Cardura</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Finasteride</mesh_term>
    <mesh_term>Doxazosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

